TORRANCE, Calif., June 02, 2020 (GLOBE NEWSWIRE) — Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, provided today operational updates in advance of the filing of its 10-K for the year ended December 31, 2019 and its 10-Q for the first quarter of 2020.
News Ticker
- [ September 28, 2023 ] Quality Control Manager (Laboratory) – Elite Protek – Bonsall, CA Los Angeles Biotech Jobs
- [ September 28, 2023 ] STRIKE – RNs and Almost All Health Care Staff to Strike St. Francis Medical Center 10/9 – 10/13 Los Angeles Biotech News
- [ September 28, 2023 ] Medical Laboratory Scientist (Generalist) – Clinical Laboratory – VIR Consultant LLC – Santa Monica, CA Los Angeles Biotech Jobs
- [ September 28, 2023 ] TAE Life Sciences Celebrates Collaboration Milestones and Unveils Alphabeam for in-hospital BNCT at ASTRO 2023 Annual Meeting Los Angeles Biotech News
- [ September 28, 2023 ] Alfred Mann Foundation Rebrands as huMannity Medtec, Unveiling a Bold, Future-Focused Identity Los Angeles Biotech News
Copyright © 2023 Biotech Networks, LLC
